Understand the source comparison
Peptide Research Protocol Comparison for Lyme Disease
Thymosin Alpha-1 TLR activation on dendritic cells, shifts cytokine profile toward IL-10, enhances thymic T-cell output 1.6–3.2mg subcutaneous Twice weekly 12–16 weeks First-line choice for immune reconstitution in PTLDS. Addresses root dysregulation rather th
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR activation on dendritic cells, shifts cytokine profile toward IL-10, enhances thymic T-cell output
- 1.6–3.2mg subcutaneous
- Twice weekly
- 12–16 weeks
- First-line choice for immune reconstitution in PTLDS. Addresses root dysregulation rather than symptom suppression
- LL-37
- Antimicrobial peptide with FPR2-mediated immune modulation, reduces biofilm formation, modulates neutrophil activity
- 2–5mg subcutaneous
- Daily (divided doses)
- 8–12 weeks
- Investigated for persistent microbial niche reduction and immune modulation. Not a primary antimicrobial agent
- BPC-157
- VEGF pathway activation, nitric oxide modulation, accelerates connective tissue and epithelial healing
- 250–500mcg subcutaneous
- Once daily
- Addresses tissue repair deficits in joints, tendons, and gut. Mechanistically distinct from immune modulation
- Thymalin
- Thymic epithelial cell stimulation, restores T-cell maturation and output
- 5–10mg intramuscular
- Every 3–5 days
- 10–20 doses total
- Alternative to thymosin alpha-1 with longer dosing intervals. Used extensively in Eastern European immune research
- MOTS-c
- Mitochondrial-derived peptide, enhances mitochondrial biogenesis and ATP production
- 5–10mg subcutaneous
- 2–3 times weekly
- Targets mitochondrial dysfunction and fatigue mechanisms. Adjunct to immune-modulating protocols